Hanmi Pharm's Hypertension Drug HCP1803-4 Gets Phase 3 Approval... Pipeline Value Expected to Rise, but 10% Success Rate Risk Remains
Hanmi Pharmaceutical, a subsidiary of Hanmi Science, received MFDS approval for a Phase 3 clinical trial of HCP1803-4 for essential hypertension
The trial will involve 256 patients across 23 domestic hospitals, aiming to demonstrate non-inferiority and safety compared to RLD2001-2
The study is expected to last about 2 years from approval date, but may be extended depending on enrollment speed
While entering Phase 3 is a key milestone, the statistical probability of final drug approval is only about 10%, posing a significant investment risk
If successful, the drug could strengthen Hanmi Pharm's hypertension portfolio and enhance Hanmi Science's enterprise value
[AI Comprehensive Analysis]This Phase 3 approval is a positive signal for Hanmi Pharm's R&D pipeline, but given the intense competition in the hypertension market and low clinical success rates, the short-term impact on stock price may be limited. Long-term value creation requires additional clinical data and regulatory approvals.
KOSPI Filing Information
Filing: Major Management Matters Related to Investment Decision (Major Management Matters of Subsidiary) (Approval of Phase 3 Clinical Trial Plan by MFDS for HCP18034 Development)